Proteomics International Laboratories reports key progress

Proteomics International Laboratories (ASX:PIQ) has reported significant progress in its diagnostic test developments for the quarter ending 30 September 2024. The company announced a breakthrough with a 94% accurate blood test for esophageal cancer and advancements in its PromarkerD test for predicting chronic kidney disease in type 1 diabetes patients. Plans for commercial launches in the USA and Australia are set for 2025.

Proteomics International's strategic outlook and future plans

Proteomics International Laboratories is making strides in the field of predictive diagnostics and precision medicine, with important advancements in their PromarkerD and PromarkerEso tests. The PromarkerD test has expanded its potential market with impressive results for type 1 diabetes, while the PromarkerEso blood test for esophageal cancer shows high accuracy. The company is preparing for commercial launches in the USA and Australia in 2025, employing hybrid Go-to-Market strategies, including traditional licensing and direct-to-consumer pathways. The company is also focusing on refining the PromarkerEndo test for endometriosis, aiming for a Q2 CY25 launch. Financially, Proteomics International maintains a stable position with expectations of an R&D tax incentive rebate to further support its operations. The company's strategic focus and ISO certifications enhance its credibility and potential for market expansion.

Executive insights on Proteomics International's progress

The September quarter has been a significant period for Proteomics International, with major breakthroughs and advancements in our diagnostic tests. Our focus on precision diagnostics continues to align with global healthcare trends, and we are excited to bring our innovative tests to market.